JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
JW Therapeutics
JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production
JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...
JW Therapeutics’ Carteyva Approved by Macau Health Bureau
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL
JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...
JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE
China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...
JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication
JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
JW Therapeutics Presents Positive Clinical Data for Carteyva in SLE at EULAR 2024
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has presented new clinical data...
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...
JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...
JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China
JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization
China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno,...
JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
JW Therapeutics Collaborates with Juno for DLL3 CAR-T Therapy Development
China-based JW Therapeutics Co., Ltd (HKG: 2126) has issued a stock exchange announcement revealing a...